Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has issued an announcement.
Lumos Diagnostics Holdings Ltd has initiated a pediatric study for its FebriDx® device in the United States, targeting children aged 2 to 12 years. This study, supported by BARDA with significant funding, aims to expand the device’s usage to differentiate bacterial from non-bacterial acute respiratory infections in younger children, potentially increasing Lumos’ market reach significantly if successful.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. The company offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests targeting infectious and inflammatory diseases.
Average Trading Volume: 6,442,225
Technical Sentiment Signal: Buy
Current Market Cap: A$169M
Learn more about LDX stock on TipRanks’ Stock Analysis page.